Safety and immunogenicity of a respiratory syncytial virus prefusion F (RSVPreF3) candidate vaccine in older adults: phase 1/2 randomized clinical trial

I Leroux-Roels, MG Davis, K Steenackers… - The Journal of …, 2023 - academic.oup.com
Background The aim of this study was to investigate safety and immunogenicity of vaccine
formulations against respiratory syncytial virus (RSV) containing the stabilized prefusion …
被引用次数：60 相关文章
[HTML] ugent.be

[HTML][HTML] Safety and immunogenicity of a respiratory syncytial virus prefusion F (RSVPreF3) candidate vaccine in older adults: phase 1/2 randomized clinical trial

I Leroux-Roels, MG Davis, K Steenackers… - JOURNAL OF …, 2023 - biblio.ugent.be
Background The aim of this study was to investigate safety and immunogenicity of vaccine
formulations against respiratory syncytial virus (RSV) containing the stabilized prefusion …

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial.

I Leroux-Roels, MG Davis, K Steenackers… - The Journal of …, 2023 - europepmc.org
Background The aim of this study was to investigate safety and immunogenicity of vaccine
formulations against respiratory syncytial virus (RSV) containing the stabilized prefusion …

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial ()

I Leroux-Roels, MG Davis… - The journal of …, 2023 - repository.uantwerpen.be
Background The aim of this study was to investigate safety and immunogenicity of vaccine
formulations against respiratory syncytial virus (RSV) containing the stabilized prefusion …
[PDF] ugent.be

[PDF][PDF] Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial

I Leroux-Roels, MG Davis… - The Journal of …, 2023 - backoffice.biblio.ugent.be
Background. The aim of this study was to investigate safety and immunogenicity of vaccine
formulations against respiratory syncytial virus (RSV) containing the stabilized prefusion …
[PDF] oup.com

[PDF][PDF] Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial

I Leroux-Roels, MG Davis, K Steenackers… - The Journal of …, 2023 - academic.oup.com
Background The aim of this study was to investigate safety and immunogenicity of vaccine
formulations against respiratory syncytial virus (RSV) containing the stabilized prefusion …

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial

I Leroux-Roels, MG Davis… - The Journal of …, 2023 - pubmed.ncbi.nlm.nih.gov
Background The aim of this study was to investigate safety and immunogenicity of vaccine
formulations against respiratory syncytial virus (RSV) containing the stabilized prefusion …

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial

I Leroux-Roels, MG Davis, K Steenackers… - The Journal of …, 2022 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Background</jats: title>< jats: p>
The aim of this study was to investigate safety and immunogenicity of vaccine formulations …

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial.

I Leroux-Roels, MG Davis… - Journal of Infectious …, 2023 - search.ebscohost.com
Background The aim of this study was to investigate safety and immunogenicity of vaccine
formulations against respiratory syncytial virus (RSV) containing the stabilized prefusion …
[HTML] nih.gov

[HTML][HTML] Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial

I Leroux-Roels, MG Davis, K Steenackers… - The Journal of …, 2023 - ncbi.nlm.nih.gov
Background The aim of this study was to investigate safety and immunogenicity of vaccine
formulations against respiratory syncytial virus (RSV) containing the stabilized prefusion …